GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MediciNova Inc (TSE:4875) » Definitions » Institutional Ownership

MediciNova (TSE:4875) Institutional Ownership : 2.51% (As of May. 26, 2024)


View and export this data going back to 2005. Start your Free Trial

What is MediciNova Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, MediciNova's institutional ownership is 2.51%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, MediciNova's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, MediciNova's Float Percentage Of Total Shares Outstanding is 85.82%.


MediciNova Institutional Ownership Historical Data

The historical data trend for MediciNova's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediciNova Institutional Ownership Chart

MediciNova Historical Data

The historical data trend for MediciNova can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 2.68 2.71 2.67 2.66 2.68 2.65 2.66 2.64 2.52 2.51

MediciNova Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


MediciNova (TSE:4875) Business Description

Traded in Other Exchanges
Address
4275 Executive Square, Suite 300, La Jolla, CA, USA, 92037
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.

MediciNova (TSE:4875) Headlines

No Headlines